Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Work In Process (2023 - 2025)

Historic Work In Process for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.5 million.

  • Tonix Pharmaceuticals Holding's Work In Process fell 2391.19% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 2391.19%. This contributed to the annual value of $213000.0 for FY2024, which is 9161.09% down from last year.
  • According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Work In Process is $1.5 million, which was down 2391.19% from $1.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Work In Process high stood at $2.5 million for Q4 2023, and its period low was $213000.0 during Q4 2024.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's median Work In Process value was $1.4 million (recorded in 2025), while the average stood at $1.4 million.
  • Its Work In Process has fluctuated over the past 5 years, first plummeted by 9161.09% in 2024, then tumbled by 2391.19% in 2025.
  • Tonix Pharmaceuticals Holding's Work In Process (Quarter) stood at $2.5 million in 2023, then tumbled by 91.61% to $213000.0 in 2024, then surged by 597.65% to $1.5 million in 2025.
  • Its Work In Process stands at $1.5 million for Q3 2025, versus $1.3 million for Q2 2025 and $664000.0 for Q1 2025.